Switzerland’s Obseva eyes China re-start for fertility drug that failed trial
ZURICH (Reuters) – ObsEva struck a pact with China’s Yuyuan BioScience Technology to develop and commercialize the fertility drug nolasiban, the Swiss drugmaker said on Monday as it seeks to inject new life into a...
Read More